The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design
Abstract Background Hypoglycaemia, especially nocturnal, remains the main limiting factor of achieving good glycaemic control in type 1 diabetes. The effect of first generation long-acting insulin analogues in reducing nocturnal hypoglycaemia is well documented in patient with type 1 diabetes. The e...
Main Authors: | Rikke Mette Agesen, Amra Ciric Alibegovic, Henrik Ullits Andersen, Henning Beck-Nielsen, Peter Gustenhoff, Troels Krarup Hansen, Christoffer Hedetoft, Tonny Jensen, Claus Bogh Juhl, Susanne Søgaard Lerche, Kirsten Nørgaard, Hans-Henrik Parving, Lise Tarnow, Birger Thorsteinsson, Ulrik Pedersen-Bjergaard |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-07-01
|
Series: | BMC Endocrine Disorders |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12902-019-0408-x |
Similar Items
-
A prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna trial): study rationale and design
by: Kristensen Peter, et al.
Published: (2012-06-01) -
Insulin degludec is a new ultra-long-acting insulin analogue
by: Ivan Ivanovich Dedov, et al.
Published: (2014-07-01) -
Insulin (Technique) Induced Hypoglycaemia
by: Adlyne Reena Asirvatham, et al.
Published: (2017-05-01) -
Practical guide in using insulin degludec/insulin aspart: A multidisciplinary approach in Malaysia
by: Siew Pheng Chan, et al.
Published: (2023-05-01) -
Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria
by: Monika Russel-Szymczyk, et al.
Published: (2019-12-01)